AIRLINK 217.98 No Change ▼ 0.00 (0%)
BOP 10.93 No Change ▼ 0.00 (0%)
CNERGY 7.55 No Change ▼ 0.00 (0%)
FCCL 34.83 No Change ▼ 0.00 (0%)
FFL 19.32 No Change ▼ 0.00 (0%)
FLYNG 25.15 No Change ▼ 0.00 (0%)
HUBC 131.09 No Change ▼ 0.00 (0%)
HUMNL 14.56 No Change ▼ 0.00 (0%)
KEL 5.18 No Change ▼ 0.00 (0%)
KOSM 7.36 No Change ▼ 0.00 (0%)
MLCF 45.63 No Change ▼ 0.00 (0%)
OGDC 222.08 No Change ▼ 0.00 (0%)
PACE 8.16 No Change ▼ 0.00 (0%)
PAEL 44.19 No Change ▼ 0.00 (0%)
PIAHCLA 17.69 No Change ▼ 0.00 (0%)
PIBTL 8.97 No Change ▼ 0.00 (0%)
POWERPS 12.51 No Change ▼ 0.00 (0%)
PPL 193.01 No Change ▼ 0.00 (0%)
PRL 43.17 No Change ▼ 0.00 (0%)
PTC 26.63 No Change ▼ 0.00 (0%)
SEARL 107.08 No Change ▼ 0.00 (0%)
SILK 1.04 No Change ▼ 0.00 (0%)
SSGC 45.00 No Change ▼ 0.00 (0%)
SYM 21.19 No Change ▼ 0.00 (0%)
TELE 10.15 No Change ▼ 0.00 (0%)
TPLP 14.51 No Change ▼ 0.00 (0%)
TRG 67.28 No Change ▼ 0.00 (0%)
WAVESAPP 11.29 No Change ▼ 0.00 (0%)
WTL 1.70 No Change ▼ 0.00 (0%)
YOUW 4.25 No Change ▼ 0.00 (0%)
BR100 12,191 Decreased By -205.8 (-1.66%)
BR30 36,583 Decreased By -764.3 (-2.05%)
KSE100 116,255 Decreased By -1331.9 (-1.13%)
KSE30 36,603 Decreased By -461.7 (-1.25%)

Drugmaker AstraZeneca said on Monday its COVID-19 vaccine, Vaxzevria, has been approved in the European Union by the bloc’s drugs regulator as a third-dose booster in adults following a committee endorsement last week.

The vaccine can now be used as a booster following the two-dose Vaxzevria schedule or by those who have been previously vaccinated by an mRNA vaccine, such as the ones made by Pfizer and BioNTech or Moderna.

“Ensuring a longer duration of immune protection is essential to the long-term management of COVID-19 globally, and boosters can address the waning of protection over time that has been seen with all primary vaccine schedules to date,” Mene Pangalos, executive vice president of biopharmaceuticals R&D at AstraZeneca, said in a statement.

A committee of the European Medicines Agency had endorsed Vaxzevria as a booster last Thursday, just weeks after the regulator backed the use of Pfizer-BioNTech’s Comirnaty as a booster for adults previously inoculated with other vaccines.

AstraZeneca bolsters COVID therapeutics with RQ Bio deal

Several vaccine makers have indicated that most vaccinations this year will be booster shots, or first inoculations for children that are still gaining regulatory approvals globally.

Typically the final say on products’ use in the European Union is decided by the European Commission.

Comments

Comments are closed.